Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant Systems Inc – one of the largest dental implant companies in the world.
Under the terms of the agreement, BioHorizons has agreed to pay AUD $23.1 million (USD $16 million) for an exclusive license of intellectual property relating to Striate+™. Orthocell will supply BioHorizons with Striate+™products, and grant BioHorizons exclusive distribution rights for these products globally.
President and CEO of BioHorizons, Steve Boggan, said:
“We are very pleased to partner with Orthocell to offer our valued customers a dental membrane with excellent handling properties and regenerative potential. Striate+™ will be a highly complementary addition to our global biomaterials product portfolio for dental tissue regeneration.”
BioHorizons is part of Henry Shein, Inc., a leading global provider of dental implants and tissue regeneration products for dentists and dental specialists. Striate+™ will sit seamlessly amongst its portfolio of innovative dental implant and tissue regeneration products, designed to improve the lives of patients with missing teeth.